Vestmark Advisory Solutions Inc. Purchases 69,937 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Vestmark Advisory Solutions Inc. boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 40.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 244,034 shares of the company's stock after acquiring an additional 69,937 shares during the quarter. Vestmark Advisory Solutions Inc. owned 0.29% of CRISPR Therapeutics worth $9,605,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC acquired a new stake in CRISPR Therapeutics in the fourth quarter valued at approximately $39,000. Western Pacific Wealth Management LP boosted its position in CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after buying an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics in the third quarter valued at approximately $40,000. Darwin Wealth Management LLC acquired a new stake in CRISPR Therapeutics in the third quarter valued at approximately $43,000. Finally, Spire Wealth Management boosted its position in CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after buying an additional 1,482 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares of the company's stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John Greene bought 7,000 shares of the firm's stock in a transaction dated Wednesday, February 26th. The shares were acquired at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the transaction, the director now owns 7,000 shares of the company's stock, valued at $313,950. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 4.10% of the company's stock.

Remove Ads

CRISPR Therapeutics Stock Up 5.1 %

CRSP traded up $2.22 during midday trading on Friday, hitting $45.53. The company had a trading volume of 1,884,937 shares, compared to its average volume of 2,267,393. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $81.73. The company has a market capitalization of $3.91 billion, a price-to-earnings ratio of -10.42 and a beta of 1.77. The stock's 50 day moving average price is $42.79 and its 200 day moving average price is $45.77.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Research analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CRSP. StockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a research report on Thursday, February 13th. Truist Financial lifted their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Bank of America cut their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Barclays lifted their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $73.11.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.